These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease. Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967 [TBL] [Abstract][Full Text] [Related]
8. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589 [TBL] [Abstract][Full Text] [Related]
9. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315 [TBL] [Abstract][Full Text] [Related]
10. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603 [TBL] [Abstract][Full Text] [Related]
11. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab. Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848 [TBL] [Abstract][Full Text] [Related]
12. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249 [TBL] [Abstract][Full Text] [Related]
13. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458 [TBL] [Abstract][Full Text] [Related]
14. Blocking GPR15 Counteracts Integrin-dependent T Cell Gut Homing in Vivo. Schramm S; Liu LJ; Saad M; Dietz L; Dedden M; Müller TM; Atreya I; Voskens CJ; Atreya R; Neurath MF; Zundler S J Crohns Colitis; 2024 Aug; 18(7):1162-1172. PubMed ID: 38243565 [TBL] [Abstract][Full Text] [Related]
15. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells. Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660 [TBL] [Abstract][Full Text] [Related]
16. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Boden EK; Shows DM; Chiorean MV; Lord JD Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476 [TBL] [Abstract][Full Text] [Related]